论文部分内容阅读
目的探究舒洛地特注射液治疗缺血性脑卒中患者的疗效与安全性。方法选取2015年8月~2016年1月本院收治的96例缺血性脑卒中患者,并设为观察组,采用舒洛地特联合依达拉奉治疗,以同期收治的70例缺血性脑卒中患者作为对照组,单纯采用依达拉奉治疗,采用欧洲脑卒中评分量表(European Stroke Scale,ESS)比较2组患者治疗前后的评分改善状况,并比较2组患者的疗效及安全性。结果观察组患者的ESS评分改善情况显著优于对照组(P<0.05);观察组患者总有效率为94.79%(91/96),显著高于对照组的82.86%(58/70)(P<0.05);2组患者治疗期间均无明显药物相关不良反应发生,安全性比较无显著差异(P>0.05)。结论舒洛地特注射液联合依达拉奉治疗缺血性脑卒中的疗效优于单纯使用依达拉奉,且安全性好。
Objective To investigate the efficacy and safety of sulodexide injection in patients with ischemic stroke. Methods A total of 96 ischemic stroke patients admitted to our hospital from August 2015 to January 2016 were enrolled in the study. Patients in the observation group were treated with sulodentid combined with edaravone, and 70 patients with ischemic stroke Patients with stroke were treated with edaravone alone. The European Stroke Scale (ESS) was used to compare the scores of two groups before and after treatment. The curative effect and safety of the two groups were compared Sex. Results The improvement of ESS score in observation group was significantly better than that in control group (P <0.05). The total effective rate in observation group was 94.79% (91/96), which was significantly higher than that in control group (82.86%, 58/70) <0.05). There were no significant adverse drug reactions during the treatment in both groups, with no significant difference in safety (P> 0.05). Conclusion The efficacy of sulodentid injection combined with edaravone in the treatment of ischemic stroke is better than that of edaravone alone.